Shearman & Sterling represented Caris Life Sciences Inc. in the transaction.Caris Life Sciences Inc. executed an $830 million growth equity round. As a result of the…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
